Fasoracetam - Aevi Genomic Medicine

Drug Profile

Fasoracetam - Aevi Genomic Medicine

Alternative Names: AEVI-001; Fasoracetam; LAM 105; MDGN-001; NFC 1; NS 105

Latest Information Update: 13 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nippon Shinyaku
  • Developer Aevi Genomic Medicine
  • Class Neuroprotectants; Nootropics; Small molecules
  • Mechanism of Action Cholinergic receptor agonists; GABA B receptor antagonists; Metabotropic glutamate receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Attention-deficit hyperactivity disorder
  • Phase II Di George syndrome
  • Discontinued Cognition disorders; Major depressive disorder

Most Recent Events

  • 28 Aug 2017 Phase-II clinical trials in Attention-deficit hyperactivity disorder (In adolescents, In children) in USA (PO) (NCT03265119)
  • 09 Aug 2017 Aevi Genomic Medicine plans a phase II proof-of-concept trial for Pervasive child development disorders (autism spectrum disorder) in early 2018
  • 10 May 2017 Aevi Genomic plans a phase II trial for Attention-deficit hyperactivity disorder in the second half of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top